A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial

Alessandro Morabito,Gennaro Daniele,Raffaele Costanzo,Adolfo Gino Favaretto,Virgilio Filipazzi,Antonio Rossi,Vittorio Gebbia, Federico Castiglione,Luigi Cavanna,Evaristo Maiello,Claudia Sandomenico,Laura Bonanno,Elena Piazza,Paolo Maione,Maria Carmela Piccirillo,Massimo Di Maio,Gaetano Rocco,Ciro Gallo,Francesco Perrone,Cesare Gridelli

Lung Cancer（2017）

引用 10|浏览59

暂无评分

摘要

•We proposed toxicity adjusted dosing of cisplatin-etoposide to improve the outcome of chemonaïve SCLC patients.•Adapting the dose of chemotherapy based on toxicity is feasible in most the patients.•Toxicity adjusted dosing is not associated with better outcomes in SCLC.

查看译文

关键词

Chemotherapy,Small-cell lung cancer,Toxicity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要